Quantitation of TAK-981 in human plasma via LC-MS/MS and its application in clinical trials.

ABSTRACT:

Aim

TAK-981 is a highly effective and selective inhibitor of the small ubiquitin-like modifier (SUMO) activating enzyme, and it promotes the expression of type I interferons (IFN-Is). Developing a sensitive bioanalytical assay for quantitating TAK-981 is essential in the clinical investigations for oncology drug development.

Materials & methods

TAK-981 and its stable isotope labeled compound (TAK-981¹³C₄, ¹⁵N₂) as the internal standard were employed in this LC-MS/MS assay.

Results

This assay was successfully validated from 0.1 ng/mL to 100 ng/mL with good accuracy and precision and has been applied to support clinical studies.

Conclusion

A sensitive and robust LC-MS/MS assay was validated for TAK-981 in human plasma f

SUBMITTER: Yin F 

PROVIDER: S-EPMC12367096 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature